Clinical Trial Update: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy [Phase 1]

View source ↗

Summary

Phase 1 safety study of a PD-L1 inhibitor sponsored by Bristol-Myers Squibb has been withdrawn. The study targeted hematologic malignancies including non-Hodgki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Myelogenous Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• BMS-936559 (PD-L1 inhibitor) (BMS-936559)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Hodgkin's Lymphoma, Hodgkin Lymphoma | Phase 1 | Status: WITHDRAWN